BRAF V600E — Drug Target

2 drugs 1 marketed 1 in Phase 3

All drugs that target BRAF V600E — marketed and clinical-stage. Includes 1 drug classes acting on this target.

Drug classes

Marketed (1)

Vemurafenib (VEM) · Abramson Cancer Center at Penn Medicine · BRAF inhibitor · Oncology
Vemurafenib is a small-molecule inhibitor that selectively blocks the BRAF V600E kinase mutation found in melanoma and other cancers.

Phase 3 pipeline (1)

GSK2118436 · M.D. Anderson Cancer Center · BRAF inhibitor · Oncology
GSK2118436 is a BRAF V600E inhibitor that blocks mutant BRAF kinase signaling in melanoma cells.